Related Experiment Video
Updated: Jun 2, 2026
05:10
Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach
Published on: September 15, 2023
Partial thyroid arterial embolization for the treatment of hyperthyroidism
Krzysztof Brzozowski1, Piotr Piasecki, Piotr Zięcina
1Department of Interventional Radiology, Military Institute of Health Service, Central Teaching Hospital of the Ministry of National Defence, Szaserów 128 Str, 04-141 Warsaw, Poland. k.brzoza@wp.pl
European Journal of Radiology
|April 20, 2011
Summary
Partial thyroid arterial embolization offers an effective alternative for hyperthyroidism patients unable to tolerate standard therapies. This procedure reduces goiter volume and normalizes thyroid hormone levels in most patients.
Area of Science:
- Endocrinology
- Interventional Radiology
Background:
- Hyperthyroidism management poses challenges for patients intolerant to standard therapies.
- Partial thyroid arterial embolization is explored as an alternative treatment modality.
Purpose of the Study:
- To evaluate the effectiveness of partial thyroid arterial embolization in managing hyperthyroidism.
- To assess the impact of the procedure on thyroid gland volume and hormone levels.
Main Methods:
- Fifteen patients with hyperthyroidism underwent partial thyroid gland embolization using Histoacryl and Lipiodol.
- The procedure involved embolizing one to three thyroid arteries, confirmed by selective angiography.
- Follow-up assessments were conducted on 12 patients.
Main Results:
- Embolization was well-tolerated, with transient initial increases in fT3 and fT4 levels.
- Within 12 weeks, 75% of patients achieved normal thyroid hormone levels (fT3, fT4, TSH).
- Thyroid gland volume reduced by approximately 32%, and fibrotic changes were observed long-term.
Conclusions:
- Partial thyroid arterial embolization is a viable alternative for hyperthyroid patients unsuitable for conventional treatments.
- The procedure demonstrates effectiveness in reducing goiter size and normalizing thyroid function in the medium to long term.
Related Concept Videos
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...